GoAI
Get started
Eupraxia Pharmaceuticals Inc. logo

Eupraxia Pharmaceuticals Inc.

EPRX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$6.73

−$0.03 · -0.44%

Aug 21, 4:00 PM ET

Pre-market

$6.20

−$0.53 · -7.88%

Aug 24, 4:04 AM ET

EPRX company overview

Historical prices · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

40

Expensive

Momentum

39

Weakening

Sentiment

59

Mixed

Risk resilience

42

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Biotechnology
Sector
Healthcare
Headquarters
CA

Market position

Day range

Current $6.73

52-week range

Current $6.73

Open
$6.77
Previous close
$6.76
Volume
298.01K
Market cap
225.32M USD
50-day average
$6.4876
+3.74% above average
200-day average
$7.0767
-4.90% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
221.26M USD
P/E (TTM)
-6.59×
P/B (TTM)
3.4×
P/S (TTM)
0×
EV / EBITDA
-4.15×
Earnings yield
-17.85%
Free cash flow yield
-9.82%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-65.65%
Return on assets
-62.52%
Return on invested capital
-66.57%

Financial health

Debt / equity
0.01×
Current ratio
15.12×

Financial statements

Income trends

Operating income

−53.66M USD-98.85%

Net income

−53.86M USD-111.33%
Income trends across reported periods−10.73M USD−26.41M USD−42.1M USD−57.78M USDOperating income, FY2021: −14.65M USDOperating income, FY2022: −17.62M USDOperating income, FY2023: −20.97M USDOperating income, FY2024: −26.99M USDOperating income, FY2025: −53.66M USDNet income, FY2021: −18.03M USDNet income, FY2022: −18.49M USDNet income, FY2023: −21.25M USDNet income, FY2024: −25.49M USDNet income, FY2025: −53.86M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −14.65M USD. Operating income FY2022 −17.62M USD. Operating income FY2023 −20.97M USD. Operating income FY2024 −26.99M USD. Operating income FY2025 −53.66M USD. Net income FY2021 −18.03M USD. Net income FY2022 −18.49M USD. Net income FY2023 −21.25M USD. Net income FY2024 −25.49M USD. Net income FY2025 −53.86M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold331.89K USD163.47K USD——112.38K USD
Gross profit−331.89K USD−163.47K USD——−112.38K USD
Research and development29.51M USD16.07M USD15.33M USD13.63M USD7.59M USD
Selling, general, and administrative17.1M USD10.92M USD5.63M USD3.99M USD6.97M USD
Operating expenses53.33M USD26.99M USD20.97M USD17.62M USD18.49M USD
Interest income1.41M USD1.16M USD649.75K USD431.8K USD51.55K USD
Interest expense—603.17K USD881.05K USD982.86K USD1.02M USD
Depreciation and amortization331.89K USD171.6K USD117.1K USD147.89K USD87.47K USD
Operating income−53.66M USD−26.99M USD−20.97M USD−17.62M USD−14.65M USD
Net income−53.86M USD−25.49M USD−21.25M USD−18.49M USD−18.03M USD

Company facts updated Aug 24, 2026.

EPRX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research EPRX

research.disclaimer